Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001209191-21-067685

Chief Scientific Officer sold 400 shares at $29.13 ($11,652)

  • Chief Scientific Officer acquired 400 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Hansen Gwenn · Chief Scientific Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2021-12-01 Exercise or conversion : show line 1 in the form +400 $7.26 $2,904 14,597 D
2021-12-01 Sale : show line 2 in the form −400 $29.13 $11,652 14,197 D
Open-market sales · 400 sh · avg $29.13 · $11,652

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2021-12-01 Exercise or conversion : show line 3 in the form Employee Stock Option (right to buy) −400 67,866 D
Loading xslF345X03/doc4.xml…